Paul Stamets on the Joe Rogan Experience #1385, fact-checked

What the evidence shows: Stamets is referring to "Extracts of Polypore Mushroom Mycelia Reduce Viruses in Honey Bees" (Stamets et al. 2018), co-authored with USDA and WSU researchers on mushroom extracts reducing deformed wing virus and Lake Sinai virus levels in honey bees. The publisher page (nature.com) and the NIH PubMed record both confirm the paper appeared in Scientific Reports, a Nature Portfolio journal published by Springer Nature, not in the flagship journal Nature itself; the two are editorially and statistically distinct publications, and Scientific Reports has a much higher acceptance rate and much larger annual volume than Nature's flagship title, making the "7%" figure inapplicable to where this paper actually appeared. Neither source supports a claim that this specific paper ranks in the "top 1%" of all articles ever published in Nature or Scientific Reports; no such bibliometric ranking is cited or verifiable from these two sources. The underlying scientific findings on fungal extracts reducing bee virus loads are not in dispute here, but the framing of where the paper was published and its comparative prestige is inaccurate and self-serving.

What the evidence shows: Stamets is citing a real, peer-reviewed study he co-authored: Stamets et al., "Extracts of Polypore Mushroom Mycelia Reduce Viruses in Honey Bees," Scientific Reports (2018). The paper reports that in an initial caged-bee lab trial, extracts of Fomes fomentarius (amadou) mycelium reduced deformed wing virus (DWV) levels more than 800-fold relative to controls (n=10), and in field trials, Ganoderma resinaceum (reishi) extract was associated with a 45,000-fold reduction in Lake Sinai virus (LSV) and a separate 79-fold reduction in DWV. These figures are accurately quoted from the paper's own reported results, based on qPCR-measured viral loads rather than direct measures of colony survival or bee health outcomes. The study was a single research group's trial with modest sample sizes and has not been independently replicated at the reported magnitudes by other labs; later independent studies on fungal extracts and honeybee health have tested different endpoints (e.g., bee lifespan, gut health) without reproducing these specific fold-reduction figures. The paper's competing-interests statement discloses that Paul Stamets holds patents on the use of fungal extracts for antiviral activity and honey bee health, and that co-author W.S. Sheppard received a research grant from Stamets' company, Fungi Perfecti LLC, to conduct the cage trials. The reported numbers are accurately stated, but the study is small, industry-linked, and not independently confirmed at that scale, so the results should be treated as preliminary rather than established evidence of practical antiviral efficacy in commercial beekeeping.

What the evidence shows: Stamets appears to be referring to deformed wing virus (DWV), not a virus literally named "D4 wing virus." The mechanism he describes is well supported: peer-reviewed research shows Varroa destructor mites feed on bee hemolymph and, in doing so, can inject DWV directly into a bee, a transmission route that is far more lethal than the natural oral/fecal route (as few as ~100 injected viral particles can kill a bee versus roughly 10 billion needed via feeding) and that favors more virulent viral strains. Separately, the strong association between Varroa, DWV, and high overwintering colony losses across dozens of US states is well established in the literature. Where the claim is off is the date: the varroa mite was not detected in the United States until 1987, when it was found in Florida colonies, and it then spread across the country over the following years. No evidence supports a 1984 US arrival; the "1984" figure appears to be a misremembering of the documented 1987 first detection.

What the evidence shows: Stamets attributes an 84% beehive die-off to Oklahoma roughly two years before this 2019 conversation, implying a catastrophic single-state collapse around 2017. The U.S. Department of Agriculture's National Agricultural Statistics Service (NASS), which conducts the official quarterly survey of commercial honey bee colonies, reported Oklahoma colony loss rates of 24%, 2%, 15%, and 6% across the four quarters of 2016, and 24% and 2% for the first two quarters of 2017, in its August 2017 Honey Bee Colonies report, the period corresponding to "two years" before this taping. No quarter or annual figure for Oklahoma in NASS's published data approaches 84%; nationally, quarterly losses in that same period ranged from roughly 8% to 17%. No corroborating USDA, university, or beekeeping-industry report describing an 84% Oklahoma-specific colony loss for any year in this timeframe was found. The figure as stated does not match available government data and appears to be either a misremembered statistic or a conflation with a much smaller subset (such as one operation's losses or losses from Colony Collapse Disorder specifically) rather than a true statewide loss rate.

What the evidence shows: Stamets is describing a real 2014 Johns Hopkins open-label pilot study (Johnson, Garcia-Romeu, Cosimano & Griffiths) in which 15 nicotine-dependent smokers received two or three moderate-to-high doses of psilocybin alongside cognitive behavioral therapy; a 2017 long-term follow-up of that same cohort reported that 10 of 15 participants (67%) were biologically confirmed as smoking-abstinent at the 12-month mark, matching the numbers Stamets cites. However, the study had no control or placebo group, was small (N=15) and unblinded, and its authors explicitly stated the open-label design does not permit definitive conclusions about psilocybin's efficacy -- describing it as "statistically significant" understates how limited a 15-person, uncontrolled pilot is for proving a causal effect. A larger 2026 Johns Hopkins pilot randomized controlled trial (N=82) later found psilocybin plus CBT produced significantly higher 6-month abstinence (40.5%) than nicotine-patch plus CBT (10.0%), lending some controlled support to the original pilot's promise, though that trial remained unblinded and modest in size compared with standard smoking-cessation drug trials. Overall, the specific 10/15 and 12-month figures Stamets cites are accurate, but presenting the underlying pilot as definitive proof rather than preliminary, hypothesis-generating evidence overstates its strength.

What the evidence shows: A 2013 mouse study (Catlow et al., Experimental Brain Research) found that low-dose psilocybin, but not high-dose psilocybin or saline, significantly sped up extinction of a conditioned fear response, while also affecting hippocampal neurogenesis in a dose-dependent way; the authors frame this as evidence psilocybin-class drugs merit exploration for PTSD-related treatment, not as a finding directly tested in humans. Stamets' onstage conversion of the mouse dose into a human mushroom-gram equivalent uses a simple 1:1 milligram-per-kilogram ratio, but standard pharmacology for translating animal doses to humans relies on allometric (body-surface-area) scaling, which accounts for mice having much higher metabolic rates relative to body mass; applying that standard method would suggest a substantially lower human-equivalent dose than a straight per-kilogram conversion implies. Separately, 70 kilograms equals approximately 154 pounds, not the 152 pounds Stamets stated, a minor arithmetic error. No published human trial has confirmed that psilocybin doses derived this way replicate the mouse fear-extinction effect. Overall, the underlying mouse finding is real and published, but the dose-scaling method used to translate it into a human mushroom dose does not match standard cross-species dosing methodology and has not been validated in humans.

What the evidence shows: The claim traces to a single small Japanese trial, Mori et al. (2009, Phytotherapy Research), a 16-week double-blind, placebo-controlled study of 30 adults aged 50-80 with diagnosed mild cognitive impairment (not dementia), who took roughly 3 grams per day of dried Hericium erinaceus fruiting-body powder (not mycelium extract). That trial found modestly improved scores on a dementia screening scale during treatment, but scores declined again within four weeks after supplementation stopped, and the sample size was too small to draw firm conclusions. No second published Japanese clinical trial on lion's mane and dementia or cognitive decline could be identified; a separate, larger erinacine-A mycelium trial reporting cognitive benefit in patients with mild Alzheimer's disease was conducted in Taiwan, not Japan. A 2025 systematic review of Hericium erinaceus clinical research concluded that the supplement "shows limited effectiveness in clinical trials" for cognitive outcomes, with most studies reporting only modest, short-term improvement rather than robust or lasting benefit. Current evidence therefore does not support the claim of two positive Japanese clinical studies on dementia, and the one relevant trial that does exist showed a smaller, more transient effect, using a different mushroom preparation (fruiting body, not mycelium), than implied.

What the evidence shows: Stamets describes deciding that a documented child fatality linked to baeocystin was a "false positive" and "bad science," then self-administering the compound based on that personal judgment rather than any toxicological study. Baeocystin is a minor, poorly studied alkaloid found alongside psilocybin and psilocin in some Psilocybe and related mushroom species; controlled pharmacological and toxicological data on baeocystin in humans are essentially absent from the peer-reviewed literature. A 2014 toxicology review of mushroom poisoning documents that psilocybin-containing mushrooms cause hallucinations, agitation, seizures, and hyperthermia in children, while severe organ failure and fatalities in pediatric mushroom poisonings are attributed overwhelmingly to misidentified amatoxin-containing species (e.g., Amanita phalloides) rather than to psilocybin or baeocystin specifically; it does not identify any baeocystin-specific fatality, so it neither confirms nor refutes the child-death account Stamets references. A 2022 review of psychedelic adverse effects further notes that much of the safety evidence base for rarer psychedelic compounds remains anecdotal rather than systematically studied. Because no controlled toxicity data on baeocystin exist, Stamets's uncontrolled self-experiment cannot establish the compound is safe, and his dismissal of a documented fatality as a "false positive" is a personal assertion unsupported by published toxicological evidence rather than a scientifically validated correction.

What the evidence shows: Stamets is describing his self-created 'Stamets stack' (psilocybin, niacin, and lion's mane mushroom), a microdosing protocol he has promoted publicly but which has not been tested in any published clinical trial. The niacin flush reaction he describes is real and well documented: niacin doses in the gram range (well above the 100-200 mg microdosing amounts he cites) commonly cause a prostaglandin-mediated flushing, itching, and burning-skin reaction, and this effect is dose-dependent, per the NIH Office of Dietary Supplements. However, no peer-reviewed research has examined whether adding niacin to psilocybin functions as a deliberate abuse deterrent, and no clinical or pharmacological literature supports the specific mechanism or intent Stamets describes. The claim mixes an accurate, independently documented pharmacological fact (niacin flush is real and dose-related) with an unstudied, self-promoted behavioral hypothesis (that this flush reliably deters someone from taking a larger psilocybin dose). Current status: the flush mechanism itself is well-supported, but the abuse-deterrent framing and the broader 'Stamets stack' protocol remain unverified and unsupported by clinical evidence.

What the evidence shows: Stamets attributes two prior mass extinctions, roughly 250 million and 65 million years ago, to asteroid impacts. That is correct for only one of the two: the end-Cretaceous (K-Pg) extinction ~66 million years ago is well-supported by geological evidence of the Chicxulub impact in Mexico and is the extinction most strongly linked to an asteroid strike. The extinction ~252 million years ago (end-Permian, the largest known mass extinction) is attributed by current scientific consensus primarily to prolonged Siberian Traps volcanism, which drove severe global warming, ocean acidification, and anoxia -- not an asteroid impact; no confirmed impact crater or definitive extraterrestrial signature of sufficient scale has been established for that event. The broader framing that Earth is currently undergoing a human-driven "sixth mass extinction" is a widely used concept in conservation biology, though its precise rate and classification relative to the "Big Five" extinctions remain subjects of ongoing scientific discussion. Overall, Stamets's statement combines an accurate claim (the 66-million-year-ago asteroid impact) with an inaccurate one (asteroid impact as the cause of the 252-million-year-ago extinction), making the combined claim misleading.